Compare Mesoblast Limited (MESO) vs Stitch Fix Inc (SFIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Stitch Fix Inc — how do they compare? Mesoblast Limited trades at $16.08 (market cap $2.17B), while Stitch Fix Inc trades at $3.94 (market cap $520.36M). The key difference: Mesoblast Limited is far larger — about 4.2× Stitch Fix Inc's market cap. Which is the better fit depends on your goals.
| MESO | SFIX | |
|---|---|---|
Market Cap | $2.17B | $520.36M |
Sector | Technology | Consumer Cyclical |
52-Week High | $20.96 | $5.83 |
52-Week Low | $12.88 | $3.06 |
Enterprise Value | $2.17B | $408.08M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Stitch Fix (SFIX) trades at $3.935, up 3.83% on the day, showing signs of a potential turnaround with recent earnings beats and a bullish technical signal. The company reported a narrowed net loss in 2025, with revenue stabilizing at $1.27 billion and a gross margin of 43.66%. Analyst consensus is a $4.75 price target, though the stock remains near historic lows, presenting a value opportunity amid improving client metrics and AI-driven personalization efforts.
The outlook for SFIX hinges on sustained execution of its turnaround strategy, with risks including consumer spending pressure and competitive threats. Upside potential exists if margin improvements and active client growth continue, but investors should weigh the company's history of net losses against recent positive momentum and analyst caution, with 63.64% holding a neutral stance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Stitch Fix Inc
Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →
